Sorrento Therapeutics, Inc.


$0.0545 USD

-$0.06 (-50.45%)

Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
Year High
Year Low
Payout Ratio
Current Ratio

Industry, Sector & symbol

Stock Exchange London Stock Exchange
CEO Dr. Henry H. Ji Ph.D.
Industry Pharmaceuticals, Biotechnology & Life Sciences
Sector Healthcare
Current Symbol 0L85.L
CIK None
Phone 858 203 4100
Currency USD
Employees 949
Country US


Debt-to-Equity Ratio -0.76
Payout Ratio 0.00
Current Ratio 0.50
Quick Ratio 0.43
Cash Ratio 0.26

Sales & Book Value

Annual Sales $62.84M
Price / Sales 0.17
Cash Flow -0.44
Price / Cash Flow -0.05
Price / Book -0.15

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts


EPS (Most Recent Fiscal Year) $-1.37
Trailing P/E Ratio -0.05
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-572.84M
Net Margin -852.80%
Pretax Margin -860.21%
Return on Equity 1008.60%
Return on Assets -120.01%

Financials Score

AltmanZ Score -9.49
Piotroski Score 4.00
Working Capital -131.84M
Total Assets 456.69M
Ebit -355.52M
Market Cap 14.88M
Total Liabilities 654.65M

Poll Results

About Sorrento Therapeutics, Inc. (LSE:0L85.L) Stock

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft vers ... us host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Frequently Asked Questions

What is the current Sorrento Therapeutics, Inc. (0L85.L) stock price?

Sorrento Therapeutics, Inc.(LSE:0L85.L) stock price is $0.0545 in the last trading session. During the trading session, 0L85.L stock reached the peak price of $0.4046 while $0.0 was the lowest point it dropped to. The percentage change in 0L85.L stock occurred in the recent session was --50.45% while the dollar amount for the price change in 0L85.L stock was -$-0.06.

0L85.L's industry and sector of operation?

The LSE listed 0L85.L is part of Pharmaceuticals, Biotechnology & Life Sciences industry that operates in the broader Healthcare sector.

Who are the executives of 0L85.L?

Dr. Xiao Xu M.D. | President of ACEA
Mr. Brian Cooley | Senior Vice President of Corporate Communications & Lymphatic Drug Development BU
Dr. Henry H. Ji Ph.D. | Chairman, President & Chief Executive Officer
Dr. Michael A. Royal J.D., M.D., MBA | SVice President & Chief Medical Officer
Dr. Alexis Nahama D.V.M. | Senior Vice President of Neurotherapeutics BU

How many employees does 0L85.L have?

Number of 0L85.L employees currently stands at 949. 0L85.L operates from 4955 Directors Place, San Diego, CA 92121, US.

Link for 0L85.L official website?

Official Website of 0L85.L is:

How do I contact 0L85.L?

0L85.L could be contacted at phone #858 203 4100 and can also be accessed through its website. 0L85.L operates from 4955 Directors Place, San Diego, CA 92121, US.

How many shares of 0L85.L are traded daily?

The average number of 0L85.L shares traded daily for last 3 months was 386.64K.

What is the market cap of 0L85.L currently?

The market value of 0L85.L currently stands at $11.03M with its latest stock price at $0.0545